About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company, 100% focused on researching and delivering new medicines and improving access to care for people living with HIV.
We are an independent pharmaceutical company established in 2009 by combining the power and expertise in the management of HIV from both GlaxoSmithKline (GSK) and Pfizer. Following a long-term collaboration on the joint development of several novel integrase inhibitors we were joined by Shionogi in 2012.
Our current portfolio of twelve HIV treatments generated annual sales of £1.5 billion in 2014 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are completely dedicated to finding new ways to limit the impact of HIV on the 35 million people living with the virus and understanding how best to prevent and treat the disease.
Our dedicated staff of over 700 people are located in 15 countries and three regional hubs. We extend this geographical reach still further via our relationship with GSK. We are equipped to move quickly in response to the needs of the HIV community and have launched industry-leading access initiatives to help deliver on World Health Organisation (WHO)/UNAIDS goals to reach all those who need treatment.
In addition, we actively support community initiatives in HIV, including the Positive Action programme, by partnering with like-minded organisations that share our ethos.
HIV presents a serious global challenge. At ViiV Healthcare we are using our commitment, expertise and passion to help meet this challenge by dedicating ourselves to delivering advances in treatment and care for people living with HIV. We firmly believe that 'good enough' is never enough. Our entrepreneurial attitude encourages us to be nimble and agile, so we can best respond to the rapidly evolving epidemic.
Everyone at ViiV Healthcare feels strongly connected to HIV and understands how their individual contributions make a difference. Together, we built a company of which we can all be proud as we face the challenge of the HIV epidemic.